Evrim ŞİRİN, Ahmet Hamdi AKGÜLLE, Osman Mert TOPKAR, Ömer SOFULU, Said Erkam BAYKAN, Bülent EROL

Mid-term results of intralesional extended curettage, cauterization, and polymethylmethacrylate cementation in the treatment of giant cell tumor of bone: A retrospective case series

Objective: The aim of this study was to present the mid-term functional outcomes and recurrence rate in patients with giant cell tumor of bone (GCTB) treated by intralesional extended curettage, electrocauterization, and polymethylmethacrylate (PMMA) cementation. Methods: In this retrospective observational study, 79 consecutive patients (41 females, 38 males; mean age=39 years; age range=19-62 years) who were diagnosed and treated for GCTB between 2005 and 2017 were identified from hospital medical records. All patients were treated by intralesional extended curettage using high-speed burr, electrocauterization of the cavity, and filling the defect with PMMA. No additional local adjuvants were used. The mean follow-up period was 47 months (range=24-96). The tumors were graded according to the radiological classification system described by Campanacci. Functional outcomes were evaluated using the Musculoskeletal Tumor Society Score (MSTS) preoperatively, one year postoperatively, and at the final follow-up. Postoperative complications and recurrence rates were recorded.Results: Twenty-nine tumors were located in the distal femur, 23 in the proximal tibia, nine in the distal radius, five in the proximal humerus, five in the pelvis, three in the proximal fibula, two in the distal ulna, two in the distal tibia, and one in the second metatarsal. According to Campanacci classification, 37 tumors were grade III, 32 grade II, and 10 grade I. The mean MSTS score was 46.1% (range 40.2 to 71.4%) preoperatively, 91.7% (range 73.3% to 100%) one year postoperatively, and 86.3 % (range 66.2% to 96,1%) at the final follow-up. The overall complication rate was 7.6%; which included local tumor recurrence in four patients, superficial wound infection in one, and deep wound infection in another. The recurrence rate was 5.1% (4 patients). Recurrent tumors were located at the distal femur in three patients and proximal tibia in one. Conclusion: With satisfactory functional results and low recurrence rates at the mid-term follow-up, GCTB can be treated effectively with intralesional extended curettage, electrocauterization, and PMMA cementation.Level of Evidence: Level IV, Therapeutic study

___

1. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res 2011; 469: 1181-7. [Crossref]

2. Dahlin DC, Cupps RE, Johnson EW Jr. Giant-cell tumor: A study of 195 cases. Cancer 1970; 25: 1061-70.

3. Deveci MA, Paydas S, Gonlusen G, Ozkan C, Bicer OS, Tekin M. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases. Acta Orthop Traumatol Turc 2017; 51: 1-6. [Crossref]

4. Teixeira LE, Vilela JC, Miranda RH, Gomes AH, Costa FA, de Faria VC. Giant cell tumors of bone: nonsurgical factors associated with local recurrence. Acta Orthop Traumatol Turc 2014; 48: 136-40. [Crossref]

5. Gao ZH, Yin JQ, Xie XB, et al. Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement. BMC Musculoskelet Disord 2014; 15: doi: 10.1186/1471-2474-15-330. [Crossref]

6. Errani C, Ruggieri P, Asenzio MAN, et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010; 36: 1-7 [Crossref]

7. Fraquet N, Faizon G, Rosset P, Phillipeau JM, Waast D, Gouin F. Long bones giant cells tumors: treatment by curretage and cavity filling cementation. Orthop Traumatol Surg Res 2009; 95: 402-6. [Crossref]

8. Moon MS, Kim SS, Moon JL, Kim SS, Moon H. Treating giant cell tumours with curettage, electrocautery, burring, phenol irrigation, and cementation. J Orthop Surg 2013; 21: 209-12. [Crossref]

9. Omlor GW, Lange L, Streit M, et al. Retrospective analysis of 51 intralesionally treated cases with progressed giant cell tumor of the bone: Local adjuvant use of hydrogen peroxide reduces the risk for tumor recurrence. World J Surg Oncol 2019; 17: 73. doi: 10.1186/s12957-019-1613-9. [Crossref]

10. Algawahmed H, Turcotte R, Farrokhyar F, Ghert M. High-Speed Burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: A systematic review and meta-analysis. Sarcoma 2010; doi: 10.1155/2010/586090. Epub 2010 Jul 27. [Crossref]

11. Zuo D, Zheng L, Sun W, Fu D, Hua Y, Cai Z. Contemporary adjuvant polymethyl methacrylate cementation optimally limits recurrence in primary giant cell tumor of bone patients compared to bone grafting: a systematic review and meta-analysis. World J Surg Oncol 2013; 11: 156. doi: 10.1186/1477-7819-11-156. [Crossref]

12. Campanacci M. Giant-cell tumor and chondrosarcomas: grading, treatment and results (studies of 209 and 131 cases). Recent Results Cancer Res 1976; 54: 257-61. [Crossref]

13. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res 1993; 286: 241-6. [Crossref]

14. O’Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994; 76: 1827-33. [Crossref]

15. Hasan O, Ali M, Mustafa M, Ali A, Umer M. Treatment and recurrence of giant cell tumors of bone - A retrospective cohort from a developing country. Ann Med Surg (Lond) 2019; 48: 29-34. [Crossref]

16. Niu X, Zhang Q, Hao L, et al. Giant cell tumor of the extremity: Retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am 2012; 94: 461-7. [Crossref]

17. Sakamoto A. Joint preserved reconstruction after curettage in giant cell tumor of bone arising in the distal radius: Case report. Int J Surg Case Rep 2015; 16: 181-3. [Crossref]

18. Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of bone. Am Acad Orthop Surg 2013; 21: 118-26. [Crossref]

19. Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999; 81: 811-20. [Crossref]

20. Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant cell tumor of bone - An overview. Arch Bone Jt Surg 2016; 4: 2-9.

21. Van der Heijden L, van de Sande MA, Dijkstra PD. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones. Acta Orthop 2012; 83: 401-5. [Crossref]

22. Yu X, Xu M, Xu S, Su Q. Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation, and oral bisphosphonates. Oncol Lett 2013; 5: 447-51. [Crossref]

23. Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008; 134: 969-78. [Crossref]

24. Van der Heijden L, Dijkstra PD, Campanacci DA, Gibbons CL, van de Sande MA. Giant cell tumor with pathologic fracture: should we curette or resect? Clin Orthop Relat Res 2013; 471: 820-9. [Crossref]

25. Gortzak Y, Kandel R, Deheshi B, et al. The efficacy of chemical adjuvants on giant-cell tumour of bone. An in vitro study. J Bone Joint Surg Br 2010; 92: 1475- 9. [Crossref]

26. Aydin M, Basarir K, Armangil M, et al. Thermal necrosis induced by electrocauterization as a local adjuvant therapy in local aggressive bone tumors, what is the safe limit for surgical margins? An experimental study. Arch Orthop Trauma Surg 2015; 135: 1071-6. [Crossref]

27. Gaston CL, Bhumbra R, Watanuki M, et al. Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone? J Bone Joint Surg Br 2011; 93: 1665-9. [Crossref]

29. Radev BR, Kase JA, Askew MJ, Weiner SD. Potential for thermal damage to articular cartilage by PMMA reconstruction of a bone cavity following tumor excision: A finite element study. J Biomech 2009; 42: 1120-6. [Crossref]

30. Lin WH, Lan TY, Chen CY, Wu K, Yang RS. Similar local control between phenol- and ethanol-treated giant cell tumors of bone. Clin Orthop Relat Res 2011; 469: 3200-8. [Crossref]

31. Mittag F, Leichtle C, Kieckbusch I, et al. Cytotoxic effect and tissue penetration of phenol for adjuvant treatment of giant cell tumours. Oncol Lett 2013; 5: 1595-8. [Crossref]

32. Quint U, Müller RT, Müller G. Characteristics of phenol. Instillation in intralesional tumor excision of chondroblastoma, osteoclastoma and enchondroma. Arch Orthop Trauma Surg 1998; 117: 43-6. [Crossref]

33. Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R. Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 2001; 27: 200-2. [Crossref]

34. Knochentumoren A, Becker WT, Dohle J, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008; 90: 1060-7. [Crossref]

35. Ruggieri P, Mavrogenis AF, Ussia G, Angelini A, Papagelopoulos PJ, Mercuri M. Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor. Clin Orthop Relat Res 2010; 468: 2954-61. [Crossref]

36. Agarwal MG, Gundavda MK, Gupta R, Reddy R. Does denosumab change the giant cell tumor treatment strategy? Lessons learned from early experience. Clin Orthop Relat Res 2018; 476: 1773-82. [Crossref]

37. Campanacci L, Sambri A, Medellin MR, Cimatti P, Errani C, Donati DM. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities. Acta Orthop Traumatol Turc 2019; 53: 376-80.[Crossref]

38. Traub F, Singh J, Dickson BC, et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer 2016; 59: 1-12. [Crossref]

39. Tsukamoto S, Tanaka Y, Mavrogenis AF, Kido A, Kawaguchi M, Errani C. Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A Systematic Review. Clin Orthop Relat Res 2020; 478: 1076-85. [Crossref]

40. Tsukamoto S, Mavrogenis AF, Tanzi P, et al. Curettage as first surgery for bone giant cell tumor: adequate surgery is more important than oncology training or surgical management by high volume specialized teams. Eur J Orthop Surg Traumatol 2020; 30: 3-9. [Crossref]

41. Biscaglia R, Bacchini P, Bertoni F. Giant cell tumor of the bones of the hand and foot. Cancer 2000; 88: 2022-32.

42. Van der Heijden L, Dijkstra PDS, van de Sande MAJ, et al. The clinical approach toward giant cell tumor of bone. Oncologist 2014; 19: 550-61. [Crossref]

43. Chen L, Ding XY, Wang CS, et al. In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage. Radiol Med 2014; 119: 861-70. [Crossref]

44. Zhang J, Dong J, Yang Z, et al. Expression of ezrin, CD44, and VEGF in giant cell tumor of bone and its significance. World J Surg Oncol 2015; 13: 168. [Crossref]